Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
IDM Pharma Reports First Quarter Financial Results - May 11 2009 7:57AM
IDM Pharma Reports First Quarter Financial Results
IDM Pharma Receives Nasdaq Shareholder Equity Notification
IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification
IDM Pharma Reports 2008 Financial Results
IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
IDM Pharma Joins NORD to Raise Awareness of Rare Diseases
IDM Pharma Provides Update on Mifamurtide (MEPACT(R), L-MTP-PE) European Regulatory Status
IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)
IDM Pharma Reports Third Quarter Financial Results
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
IDM Pharma Reports Second Quarter Financial Results
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE)
IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting - May 27 2008 12:55AM
IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
IDM Pharma Reports First Quarter Financial Results - Jun 1 2008 10:53PM
IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
BenchmarkJournal.com Sector Analysis for TGIC, SYNM, ANPI and IDMI
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
